Sustained elevation of interleukin-33 in sera and synovial Xuids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: Possible association with persistent IL-1β signaling and a poor clinical response

Rheumatology International

Volumn 32, Issue 5, 2012, Pages 1397-1401

  Matsuyama, Yasushi ^a   Okazaki, Hitoaki ^a   Hoshino, Motoaki ^a   Onishi, Sachiko ^a   Kamata, Yasuyuki ^a   Nagatani, Katsuya ^a   Nagashima, Takao ^a   Iwamoto, Masahiro ^a   Yoshio, Taku ^a   Ohto Ozaki, Hiromi ^a   Tamemoto, Hiroyuki ^a   Komine, Mayumi ^a   Sekiya, Hitoshi ^a   Tominaga, Shin Ichi ^a   Minota, Seiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Interleukin 1 family; Interleukin 33; Rheumatoid arthritis; ST2; TNF inhibitor; Tumor necrosis factor

Indexed keywords

ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 33; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID LEVEL; SYNOVIOCYTE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKINS; JAPAN; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84863620903     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1854-6     Document Type: Article

References (13)

1. Maini R, Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) InXiximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939. doi:S0140673699052460
2. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, SchiV MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593. doi:10.1056/NEJM200011303432201
3. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClana-han TK, Zurawski G, MoshreW M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-490. doi:S1074-7613(05)00311-0
4. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S (2010) IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 59:143-160. doi:059020143
5. Verri WA Jr, Souto FO, Vieira SM, Almeida SC, Fukada SY, Xu D, Alves-Filho JC, Cunha TM, Guerrero AT, Mattos-Guimaraes RB, Oliveira FR, Teixeira MM, Silva JS, McInnes IB, Ferreira SH, Louzada-Junior P, Liew FY, Cunha FQ (2010) IL-33 induces neu-trophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 69:1697-1703. doi:ard.2009.122655
6. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY (2008) IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 105:10913-10918. doi:0801898105
7. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C (2009) Inhibition of inter-leukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 60:738-749. doi:10.1002/art.24305
8. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, Nagashima T, Hayakawa M, Iwamoto M, Yoshio T, Tominaga S, Minota S (2010) Increased levels of interleukin 33 in sera and synovial Xuid from patients with active rheumatoid arthritis. J Rheumatol 37:18-25. doi:jrheum.090492
9. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 66:407-409. doi:ard.2006.054205
10. Hayakawa H, Hayakawa M, Kume A, Tominaga S (2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway inXamma-tion. J Biol Chem 282:26369-26380. doi:M704916200
11. Fraser A, Moore M, Jongbloed S, Gracie A, McInnes I (2006) Elevated soluble ST2 and cytokine levels in synovial Xuids of patients with inXammatory synovitis. Ann Rheum Dis 65(Suppl 1):A10
12. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY (2004) A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 173:145-150
13. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P (2004) Combination therapy with etaner-cept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412-1419. doi:10.1002/art.20221